PT  - JOURNAL ARTICLE
AU  - Klein, Ana
AU  - Bastard, Mathieu
AU  - Hemat, Hamayoun
AU  - Singh, Saschveen
AU  - Muniz, Bruno
AU  - Manangama, Guyguy
AU  - Alayyan, Amber
AU  - Tamanna, Abdul Hakim
AU  - Barakzaie, Bashir
AU  - Popal, Nargis
AU  - Zmarial Kakar, Mohammad Azeem
AU  - Poulet, Elisabeth
AU  - Finger, Flavio
TI  - Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center run by Médecins sans Frontières in Herat, Afghanistan
AID  - 10.1101/2023.02.15.23285976
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.15.23285976
4099  - http://medrxiv.org/content/early/2023/02/16/2023.02.15.23285976.short
4100  - http://medrxiv.org/content/early/2023/02/16/2023.02.15.23285976.full
AB  - Background Though many studies on COVID have been published to date, data on COVID-19 epidemiology, symptoms, risk factors and severity in low- and middle-income countries (LMICS), such as Afghanistan are sparse.Objective To describe clinical characteristics, severity, and outcomes of patients hospitalized in the MSF COVID-19 treatment center (CTC) in Herat, Afghanistan and to assess risk factors associated with severe outcomes.Methods 1113 patients were included in this observational study between June 2020 and April 2022. Descriptive analysis was performed on clinical characteristics, complications, and outcomes of patients. Univariate description by Cox regression to identify risk factors for an adverse outcome was performed. Adverse outcome was defined as death or transfer to a level 3 intensive care located at another health facility. Finally, factors identified were included in a multivariate Cox survival analysis.Results A total of 165 patients (14.8%) suffered from a severe disease course, with a median time of 6 days (interquartile range: 2-11 days) from admission to adverse outcome. In our multivariate model, we identified male gender, age over 50, high O2 flow administered during admission, lymphopenia, anemia and O2 saturation <=93% during the first three days of admission as predictors for a severe disease course (p<0.05).Conclusion Our analysis concluded in a relatively low rate of adverse outcomes of 14.8%. This is possibly related to the fact, that the resources at an MSF-led facility are higher, in terms of human resources as well as supply of drugs and biomedical equipment, including oxygen therapy devices, compared to local hospitals. Predictors for severe disease outcomes were found to be comparable to other settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was entirely funded by Médecins Sans Frontières.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research described here has been conducted according to the principles expressed in the Declaration of Helsinki. This study was approved by the Institutional Review Board of the Afghan National Public Health Institute (Protocol A.0820.0214, 12 August 2020) and by the MSF Ethical Review board (Protocol 2043a, 20 August 2020). All patients included in the study either verbally consented for their deidentified data to be used or met the exemption criteria approved by the Ethical Review Boards (patient discharged before the study started and thus included retrospectively OR patient deceased before the verbal consent could be taken).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableDue to the nature of the study and the potential ease of identification of research participants, publication of the data underlying this study is subject to legal and ethical restrictions. The minimal data set underlying the findings of this study are available on request, in accordance with the legal framework set forth by Médecins Sans Frontières (MSF) data sharing policy (Karunakara U, PLoS Med 2013). MSF is committed to sharing and disseminating health data from its programs and research in an open, timely, and transparent manner in order to promote health benefits for populations while respecting ethical and legal obligations towards patients, research participants, and their communities. The MSF data sharing policy ensures that data will be available upon request to interested researchers while addressing all security, legal, and ethical concerns. All readers may contact the generic address data.sharing@msf.org or the corresponding authors to request the data.ARDSAcute respiratory distress syndromeBPBlood pressureCIConfidence intervalCOVID (−19)Coronavirus diseaseCRPC-reactive proteinCTCCOVID-19 treatment centerHIVHuman immunodeficiency virusHRHazard ratioICUIntensive care unitIQRInterquartile rangeLMICLow- to middle-income countryMSFMédecins Sans FrontièresPCRPolymerase chain reactionREDCapResearch Electronic Data CaptureWBCWhite blood cellWHOWorld Health Organization